Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mind Medicine (MindMed) Inc.

7.79
+0.10001.30%
Post-market: 7.910.1200+1.54%19:58 EDT
Volume:1.10M
Turnover:8.65M
Market Cap:588.56M
PE:-7.36
High:8.01
Open:7.88
Low:7.72
Close:7.69
Loading ...

MindMed to Present at Leerink’s Global Healthcare Conference 2025

Business Wire
·
04 Mar

Press Release: MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Dow Jones
·
20 Feb

Mind Medicine (MNMD) Advances Groundbreaking LSD Treatment

TIPRANKS
·
06 Feb

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

Dow Jones
·
05 Feb

Mind Medicine doses first patient in Panorama study

TIPRANKS
·
30 Jan

Mind Medicine (MindMed) Inc - Topline Data Expected in Second Half of 2026

THOMSON REUTERS
·
30 Jan

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of Mm120 in Generalized Anxiety Disorder

THOMSON REUTERS
·
30 Jan

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Business Wire
·
30 Jan

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive
·
20 Jan

5 Biotech Breakthrough Stocks to Watch in 2025

Zacks
·
23 Dec 2024

Chardan Initiates Coverage on Mind Medicine With Buy Rating, $20 Price Target

MT Newswires Live
·
20 Dec 2024

Mind Medicine initiated with a Buy at Chardan

TIPRANKS
·
20 Dec 2024

Mind Medicine to Join Nasdaq Biotechnology Index

MT Newswires Live
·
19 Dec 2024

Mind Medicine to be added to Nasdaq Biotechnology Index December 23.

TIPRANKS
·
19 Dec 2024

MindMed to Be Added to the Nasdaq Biotechnology Index

Business Wire
·
19 Dec 2024

Mind Medicine Price Target Maintained With a $20.00/Share by Oppenheimer

Dow Jones
·
18 Dec 2024

Mind Medicine (MNMD) Receives a Buy from Oppenheimer

TIPRANKS
·
17 Dec 2024

MindMed Begins Phase 3 LSD Study for Anxiety

TIPRANKS
·
17 Dec 2024

Mind Medicine Doses First Patient in Phase 3 Study of MM120 to Treat Generalized Anxiety Disorder

MT Newswires Live
·
16 Dec 2024

BRIEF-Mindmed Announces First Patient Dosed In Phase 3 Voyage Study Of Mm120 In Generalized Anxiety Disorder (Gad)

Reuters
·
16 Dec 2024